STNM01, the RNA oligonucleotide targeting carbohydrate sulfotransferase 15, as second-line therapy for chemotherapy-refractory patients with unresectable pancreatic cancer: An open label, phase I/IIa trial

BACKGROUND: The impact of stroma-targeting therapy on tumor immune suppression is largely unexplored. An RNA oligonucleotide, STNM01, has been shown to repress carbohydrate sulfotransferase 15 (CHST15) responsible for tumor proteoglycan synthesis and matrix remodeling. This phase I/IIa study aimed t...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujisawa, Toshio, Tsuchiya, Takayoshi, Kato, Motohiko, Mizuide, Masafumi, Takakura, Kazuki, Nishimura, Makoto, Kutsumi, Hiromu, Matsuda, Yoko, Arai, Tomio, Ryozawa, Shomei, Itoi, Takao, Isayama, Hiroyuki, Saya, Hideyuki, Yahagi, Naohisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9678806/
https://www.ncbi.nlm.nih.gov/pubmed/36425867
http://dx.doi.org/10.1016/j.eclinm.2022.101731

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9678806/
https://www.ncbi.nlm.nih.gov/pubmed/36425867
http://dx.doi.org/10.1016/j.eclinm.2022.101731

Ejemplares similares